Weiss Multi-Strategy Advisers’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-5,725
| Closed | -$771K | – | 41 |
|
|
2023
Q4 | $771K | Sell |
5,725
-14,027
| -71% | -$1.82M | 0.02% | 452 |
|
|
2023
Q3 | $2.67M | Sell |
19,752
-6,517
| -25% | -$890K | 0.06% | 338 |
|
|
2023
Q2 | $3.76M | Sell |
26,269
-1,428
| -5% | -$210K | 0.08% | 349 |
|
|
2023
Q1 | $3.85M | Buy |
27,697
+11,950
| +76% | +$1.61M | 0.09% | 312 |
|
|
2022
Q4 | $2.13M | Sell |
15,747
-87,861
| -85% | -$11M | 0.06% | 377 |
|
|
2022
Q3 | $11.4M | Buy |
103,608
+47,754
| +85% | +$6.06M | 0.3% | 109 |
|
|
2022
Q2 | $7.38M | Buy |
55,854
+11,443
| +26% | +$1.5M | 0.22% | 158 |
|
|
2022
Q1 | $5.89M | Sell |
44,411
-667
| -1% | -$80K | 0.14% | 240 |
|
|
2021
Q4 | $5.25M | Buy |
45,078
+2,952
| +7% | +$347K | 0.12% | 228 |
|
|
2021
Q3 | $5.06M | Buy |
+42,126
| New | +$4.9M | 0.11% | 248 |
|
|
2021
Q1 | – | Sell |
-78,569
| Closed | -$7.86M | – | 701 |
|
|
2020
Q4 | $7.86M | Buy |
78,569
+33,484
| +74% | +$3.55M | 0.15% | 187 |
|
|
2020
Q3 | $4.94M | Sell |
45,085
-7,415
| -14% | -$825K | 0.13% | 226 |
|
|
2020
Q2 | $5.55M | Sell |
52,500
-7,121
| -12% | -$735K | 0.16% | 198 |
|
|
2020
Q1 | $5.33M | Buy |
59,621
+1,621
| +3% | +$153K | 0.21% | 152 |
|
|
2019
Q4 | $5.78M | Buy |
58,000
+3,000
| +5% | +$282K | 0.09% | 280 |
|
|
2019
Q3 | $4.9M | Sell |
55,000
-5,000
| -8% | -$434K | 0.1% | 257 |
|
|
2019
Q2 | $4.95M | Sell |
60,000
-15,000
| -20% | -$1.18M | 0.13% | 175 |
|
|
2019
Q1 | $6.07M | Sell |
75,000
-2,500
| -3% | -$197K | 0.15% | 172 |
|
|
2018
Q4 | $5.89M | Sell |
77,500
-5,280
| -6% | -$412K | 0.25% | 115 |
|
|
2018
Q3 | $6.55M | Buy |
82,780
+879
| +1% | +$66.5K | 0.17% | 156 |
|
|
2018
Q2 | $5.75M | Buy |
81,901
+11,901
| +17% | +$856K | 0.14% | 201 |
|
|
2018
Q1 | $4.9M | Buy |
70,000
+12,000
| +21% | +$831K | 0.16% | 184 |
|
|
2017
Q4 | $4.03M | Buy |
58,000
+13,000
| +29% | +$877K | 0.1% | 224 |
|
|
2017
Q3 | $3.05M | Buy |
45,000
+25,000
| +125% | +$1.58M | 0.11% | 246 |
|
|
2017
Q2 | $1.36M | Sell |
20,000
-5,000
| -20% | -$327K | 0.06% | 336 |
|
|
2017
Q1 | $1.56M | Sell |
25,000
-7,500
| -23% | -$437K | 0.06% | 327 |
|
|
2016
Q4 | $1.78M | Sell |
32,500
-2,500
| -7% | -$142K | 0.09% | 220 |
|
|
2016
Q3 | $2.3M | Buy |
35,000
+372
| +1% | +$24.3K | 0.14% | 196 |
|
|
2016
Q2 | $2.09M | Sell |
34,628
-32,872
| -49% | -$1.91M | 0.16% | 181 |
|
|
2016
Q1 | $3.8M | Sell |
67,500
-2,500
| -4% | -$150K | 0.17% | 173 |
|
|
2015
Q4 | $4.75M | Sell |
70,000
-6,000
| -8% | -$393K | 0.33% | 81 |
|
|
2015
Q3 | $4.84M | Buy |
76,000
+1,000
| +1% | +$65.8K | 0.21% | 94 |
|
|
2015
Q2 | $4.78M | Buy |
75,000
+47,200
| +170% | +$3.23M | 0.19% | 143 |
|
|
2015
Q1 | $1.9M | Sell |
27,800
-2,200
| -7% | -$153K | 0.08% | 249 |
|
|
2014
Q4 | $2.11M | Sell |
30,000
-5,000
| -14% | -$358K | 0.07% | 208 |
|
|
2014
Q3 | $2.5M | Buy |
35,000
+5,000
| +17% | +$366K | 0.06% | 279 |
|
|
2014
Q2 | $2.23M | Sell |
30,000
-45,000
| -60% | -$3.25M | 0.05% | 322 |
|
|
2014
Q1 | $4.87M | Sell |
75,000
-5,000
| -6% | -$323K | 0.1% | 230 |
|
|
2013
Q4 | $4.75M | Buy |
+80,000
| New | +$4.35M | 0.1% | 249 |
|
|
2013
Q3 | – | Sell |
-25,000
| Closed | -$1.18M | – | 902 |
|
|
2013
Q2 | $1.18M | Buy |
+25,000
| New | +$1.27M | 0.03% | 367 |
|
Other funds holding AZN
Weiss Multi-Strategy Advisers's AZN Position: Q1 2024 in Review
Weiss Multi-Strategy Advisers sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 5,725 shares — an estimated $771K sold.
Weiss Multi-Strategy Advisers first reported a position in AZN in Q2 2013 and held it in 40 quarters. The position peaked at $11.4M in Q3 2022. 1,141 funds tracked by Wall St. Rank hold AZN as of Q1 2024.
- Weiss Multi-Strategy Advisers reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
- Weiss Multi-Strategy Advisers sold 5,725 AstraZeneca shares in Q1 2024, an estimated $771K.
- Weiss Multi-Strategy Advisers first reported a position in AstraZeneca in Q2 2013 and held it in 40 quarters.
- Weiss Multi-Strategy Advisers's AstraZeneca position peaked at $11.4M in Q3 2022.
- 1,141 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.
Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.